• Genenta received a Nasdaq notice on April 10, 2026 for failing to meet minimum $1 bid-price requirement under Listing Rule 5550(a)(2).
• Nasdaq granted 180-day compliance window through Oct. 7, 2026 to regain compliance.
• Failure to cure by deadline could open path to another 180-day extension if Genenta qualifies for Nasdaq Capital Market standards, excluding bid price.
• Company is weighing remediation options, including potential reverse stock split if needed.
• Notice does not trigger immediate change to listing status for Genenta ADS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genenta Science S.p.A. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-016540), on April 14, 2026, and is solely responsible for the information contained therein.